{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:20:15Z","timestamp":1788826815255,"version":"build-2803163510"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Classic Hodgkin lymphoma (cHL) exhibits a bimodal age distribution with incidence peaks in adolescents and young adults (AYAs) aged 15-39 years and in older adults over 50 years. The unique biology of cHL, characterized by a tumor microenvironment (TME) composed predominantly of non-malignant immune and stromal cells, plays a pivotal role in supporting Hodgkin and Reed-Sternberg (HRS) cells, the malignant cells of cHL. Understanding the role of the TME in cHL and its age-related differences is crucial for deciphering differential disease etiologies and developing biomarker-driven targeted therapies. Recent technical advances in single-cell sequencing and multiplexed spatial imaging have revealed age-related differences in TME composition and function, including key cellular interactions, leading to the development of age-specific prognostic indicators. In addition, advances in our ability to isolate nucleic acids from HRS cells have accelerated our understanding of the molecular alterations in cHL, many of which drive interactions within the TME. Molecular differences in cHL between pediatric\/AYA and older adult patients have also emerged. This review summarizes the unique biology of cHL and its TME in children, adolescents, and young adults, highlighting recent breakthroughs in our understanding of cHL biology, differences across the age spectrum, and advances in biomarker development.<\/jats:p>","DOI":"10.3389\/fonc.2025.1515250","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T04:14:43Z","timestamp":1746072883000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Tumor-microenvironment and molecular biology of classic Hodgkin lymphoma in children, adolescents, and young adults"],"prefix":"10.3389","volume":"15","author":[{"given":"Tomohiro","family":"Aoki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Wierzbicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Giulino-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-537480","article-title":"Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma","volume":"125","author":"Connors","year":"2015","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk hodgkin's lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1107.1107","article-title":"Pembrolizumab in Relapsed\/Refractory classical Hodgkin lymphoma: Primary end point analysis of the phase 2 keynote-087 study","volume":"128","author":"Moskowitz","year":"2016","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","author":"Alig","year":"2023","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1387","article-title":"Nivolumab in the treatment of Hodgkin lymphoma","volume":"23","author":"Ansell","year":"2017","journal-title":"Clin Cancer Research: Off J Am Assoc Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30580","article-title":"Children\u2019s oncology group's 2023 blueprint for research: Hodgkin lymphoma","author":"Castellino","year":"2023","journal-title":"Pediatr Blood Cancer."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017147","article-title":"Novel insights into Hodgkin lymphoma biology by single cell analysis","author":"Aoki","year":"2022","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01761","article-title":"Biology in practice: Harnessing the curative potential of the immune system in lymphoid cancers","volume":"39","author":"Aoki","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of hodgkin's lymphoma","volume":"9","author":"Kuppers","year":"2009","journal-title":"Nat Rev Cancer."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary hodgkin and reed-sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001012","article-title":"Genomic analyses of flow-sorted hodgkin reed-sternberg cells reveal complementary mechanisms of immune evasion","volume":"3","author":"Wienand","year":"2019","journal-title":"Blood Adv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.22725554","article-title":"Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of hodgkin and reed sternberg cells","author":"Maura","year":"2023","journal-title":"Blood Cancer Discovery"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.525724","article-title":"Comparing adult and pediatric hodgkin lymphoma in the surveillance, epidemiology and end results program, 1988-2005: an analysis of 21 734 cases","volume":"51","author":"Bazzeh","year":"2010","journal-title":"Leukemia lymphoma."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01799","article-title":"Classic Hodgkin lymphoma in adolescents and young adults","volume":"42","author":"Kelly","year":"2024","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401097","article-title":"Epstein-barr virus and hodgkin\u2019s disease: further evidence for the three disease hypothesis","volume":"12","author":"Armstrong","year":"1998","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.6310","article-title":"Epstein-barr virus as a marker of survival after hodgkin\u2019s lymphoma: a population-based study","volume":"23","author":"Keegan","year":"2005","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.050146","article-title":"Contribution of the epstein barr virus to the molecular pathogenesis of hodgkin lymphoma","volume":"60","author":"Kapatai","year":"2007","journal-title":"J Clin Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.701","article-title":"Impact of latent epstein-barr virus infection on outcome in children and adolescents with Hodgkin\u2019s lymphoma","volume":"23","author":"Claviez","year":"2005","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.3390\/cancers14174297","article-title":"Impact of tumour epstein-barr virus status on clinical outcome in patients with classical hodgkin lymphoma (cHL): A review of the literature and analysis of a clinical trial cohort of children with cHL","volume":"14","author":"Nohtani","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000334","article-title":"Novel biomarker approaches in classic hodgkin lymphoma","volume":"24","author":"Aoki","year":"2018","journal-title":"Cancer J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of hodgkin\u2019s lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1311","DOI":"10.1002\/cnr2.1311","article-title":"The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes","volume":"4","author":"Nagpal","year":"2021","journal-title":"Cancer Rep (Hoboken)."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32659","article-title":"Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy","volume":"126","author":"Bair","year":"2020","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-839217","article-title":"Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma","volume":"132","author":"Chow","year":"2018","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124531","article-title":"Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival","volume":"10","author":"Barros","year":"2015","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27314","article-title":"Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is\u00a0modulated by age and epstein-barr virus infection","volume":"131","author":"Barros","year":"2012","journal-title":"Int J Cancer."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1182\/blood-2008-07-168096","article-title":"Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome","volume":"113","author":"Chetaille","year":"2009","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.957208","article-title":"PD-1 and LAG-3 expression in EBV-associated pediatric Hodgkin lymphoma has influence on survival","volume":"12","author":"Jimenez","year":"2022","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.896629","article-title":"Classical hodgkin lymphoma with positive epstein-barr virus status is associated with more FOXP3 regulatory T cells","volume":"22","author":"Pavlovic","year":"2016","journal-title":"Med Sci Monit"},{"key":"B40","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","article-title":"Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma","volume":"31","author":"Scott","year":"2013","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011941","article-title":"A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma","volume":"139","author":"Johnston","year":"2022","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for reed-sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102887","article-title":"Therapeutic updates for relapsed and refractory classical hodgkin lymphoma","volume":"12","author":"Voorhees","year":"2020","journal-title":"Cancers"},{"key":"B44","article-title":"Nivolumab in the treatment of hodgkin lymphoma","author":"Ansell","year":"2016","journal-title":"Clin Cancer Research: Off J Am Assoc Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"JCO2301115","DOI":"10.1200\/JCO.23.01115","article-title":"Spatially resolved tumor microenvironment predicts treatment outcomes in Relapsed\/Refractory Hodgkin lymphoma","author":"Aoki","year":"2023","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.03.021","article-title":"Tumor associated macrophages in relapsed and refractory hodgkin lymphoma","volume":"37","author":"Casulo","year":"2013","journal-title":"Leuk Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2693","article-title":"Serum CD163 and TARC as disease response biomarkers in classical hodgkin lymphoma","volume":"19","author":"Jones","year":"2013","journal-title":"Clin Cancer Research: Off J Am Assoc Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01115","article-title":"Spatially resolved tumor microenvironment predicts treatment outcomes in Relapsed\/Refractory hodgkin lymphoma","volume":"42","author":"Aoki","year":"2024","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2023.05.24.542195","DOI":"10.1136\/jitc-2023-SITC2023.0125","article-title":"Single cell spatial analysis and biomarker discovery in Hodgkin lymphoma","author":"Xu","year":"2023","journal-title":"bioRxiv"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4(+) regulatory T-cell-rich and exhausted t-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discovery"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2105822118","article-title":"Single-cell profiling reveals the importance of CXCL13\/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma","volume":"118","author":"Aoki","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015575","article-title":"Spatial and molecular profiling of the mononuclear phagocyte network in classic Hodgkin lymphoma","volume":"141","author":"Stewart","year":"2023","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.05.024","article-title":"The prognostic impact of tumour-associated macrophages and reed-sternberg cells in paediatric Hodgkin lymphoma","volume":"49","author":"Gupta","year":"2013","journal-title":"Eur J Cancer."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e24661","DOI":"10.1002\/jcla.24661","article-title":"Flow cytometry assessment of reactive T-cells distinguishes classic Hodgkin lymphoma from benign lymphadenopathy in children","volume":"36","author":"Gao","year":"2022","journal-title":"J\u00a0Clin Lab Anal"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20459","article-title":"Overexpression of CD7 in classical Hodgkin lymphoma-infiltrating t lymphocytes","volume":"76","author":"Seegmiller","year":"2009","journal-title":"Cytometry B Clin Cytom."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1839651","article-title":"LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma","volume":"62","author":"Moerdler","year":"2021","journal-title":"Leuk Lymphoma."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.53.9.666","article-title":"Laser capture microdissection in pathology","volume":"53","author":"Fend","year":"2000","journal-title":"J Clin Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2012.03.028","article-title":"Strategies for immunophenotyping and purifying classical Hodgkin lymphoma cells from lymph nodes by flow cytometry and flow cytometric cell sorting","volume":"57","author":"Fromm","year":"2012","journal-title":"Methods"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a\u00a0prospective study","volume":"106","author":"Camus","year":"2021","journal-title":"Haematologica"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0541-6","article-title":"Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma","volume":"34","author":"Desch","year":"2020","journal-title":"Leukemia"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"101514","DOI":"10.1016\/j.beha.2023.101514","article-title":"Hodgkin lymphoma: A disease shaped by the tumor micro- and macroenvironment","volume":"36","author":"Masel","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.3390\/ijms20215503","article-title":"Immune and inflammatory cells of the tumor microenvironment represent novel therapeutic targets in classical hodgkin lymphoma","volume":"20","author":"Calabretta","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-22-0128","article-title":"Molecular evolution of classic Hodgkin lymphoma revealed through whole-genome sequencing of hodgkin and reed sternberg cells","volume":"4","author":"Maura","year":"2023","journal-title":"Blood Cancer Discovery"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000396","article-title":"The genetics of Hodgkin lymphoma: an overview and clinical implications","volume":"29","author":"Borchmann","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"20406207221149245","DOI":"10.1177\/20406207221149245","article-title":"Genetic lesions and targeted therapy in Hodgkin lymphoma","volume":"14","author":"Li","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"JCO2301867","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma","author":"Heger","year":"2024","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174139","article-title":"Multi-dimensional molecular and tumor-microenvironment analysis of classic hodgkin lymphoma","volume":"142","author":"Aoki","year":"2023","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2025.03.18.643177","DOI":"10.1101\/2025.03.18.643177","article-title":"Multidimensional characterization of cellular ecosystems in Hodgkin lymphoma","author":"Aoki","year":"2025","journal-title":"bioRxiv"},{"key":"B76","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.786","article-title":"Scientific techniques in adolescent and young adult classic Hodgkin lymphoma","volume":"4","author":"Maura","year":"2023","journal-title":"EJHaem"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1515250\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T04:14:44Z","timestamp":1746072884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1515250\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":78,"alternative-id":["10.3389\/fonc.2025.1515250"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1515250","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"article-number":"1515250"}}